Tectonic Therapeutic, Inc.
TECXAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Oct 11, 2026 | UBS | Alice Nettleton | $26.00(+11%) | $23.33 | TheFly |
| Sep 30, 2026 | Oppenheimer | Leland Gershell | $80.00(+243%) | $23.34 | StreetInsider |
| May 26, 2026 | Raymond James | Martin Auster | $81.00(+178%) | $29.12 | StreetInsider |
| Apr 13, 2026 | Stifel Nicolaus | $75.00(+150%) | $29.96 | TheFly | |
| Jan 8, 2026 | Truist Financial | Danielle Brill | $60.00(+185%) | $21.05 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Wells Fargo | maintain | Overweight | Aug 7, 2026 |
| Raymond James | upgrade | Outperform →Strong Buy | May 26, 2026 |
| Truist Securities | maintain | Buy | Jan 8, 2026 |
| Mizuho | maintain | Outperform | May 15, 2025 |
| Wells Fargo | maintain | Overweight | Mar 21, 2025 |
| Wells Fargo | maintain | Overweight | Jan 31, 2025 |
| Wells Fargo | maintain | Overweight | Nov 12, 2024 |
| Leerink Partners | maintain | Outperform | Nov 11, 2024 |
Earnings History
Next report: Feb 25, 2027 · EPS est. $-1.38| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Nov 5, 2026 | $-1.08 | $-1.32 | — | — |
| Aug 6, 2026 | $-1.18 | $-1.35 | — | — |
| May 7, 2026 | $-1.34 | $-1.16 | — | — |
| Feb 26, 2026 | $-1.03 | $-1.11 | — | — |
| Nov 6, 2025 | $-1.02 | $-1.05 | — | — |
| Aug 7, 2025 | $-1.07 | $-0.98 | — | — |
| May 8, 2025 | $-0.93 | $-1.10 | — | — |
| Mar 20, 2025 | $-0.84 | $-1.39 | — | — |
News
WATERTOWN, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic” or the “Company”), a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced financial results for the third quarter ended September 30, 2026, and provided an overview of recent business highlights.
Tectonic Therapeutic, Inc. (NASDAQ: TECX - Get Free Report) has earned a consensus rating of "Moderate Buy" from the ten analysts that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, five have issued a buy rating and two have assigned
U.S. FDA has granted Fast Track designation for TX2100 in HHT and cleared the Investigational New Drug (IND) application for the TX2100 Phase 1b clinical trial in HHT patients in the U.S. TX2100 Phase 1a clinical trial topline results demonstrated single ascending doses of TX2100 were generally safe and well-tolerated in healthy adult volunteers Company plans to initiate an open-label TX2100 Phase 1b clinical trial in patients with hematologic-support dependent HHT by year-end 2026, and initiate…
Tectonic Therapeutic, Inc. (NASDAQ: TECX - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the eight ratings firms that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, four have assigned a buy recommendation and two have given
WATERTOWN, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced that Alise Reicin, MD, President and Chief Executive Officer, will participate in a fireside chat at the upcoming Morgan Stanley 24th Annual Global Healthcare Conference.
Tectonic Therapeutic offers a validated, severity-enriched trial design for TX45 in CpcPH-HFpEF, with external support from Merck's CADENCE results. Phase 1b TX45 data show promising hemodynamic effects, and the company's cash runway extends through Q1 2029, reducing near-term financing risk. TX2100, a mechanistically distinct candidate for HHT, further validates the GEODe platform, with Phase 1a results expected by Q3 2026.